Global Contrast-Enhanced Ultrasound (CEUS)

Click on any country shaded in orange to see the commercially available agent(s).
 

(Agent(s) commercially available)

 

 

(No agent commercially available at this time)

 

* See package inserts for approved indications. Note that this “Global CEUS” map lists certain ultrasound contrast agents under different product names (i.e., Lumason/SonoVue and Definity/Luminity). ICUS will update this map as additional agents are approved throughout the world.

 

ICUS does not endorse or recommend the use of any ultrasound contrast agent or other medical product. In addition, ICUS does not warrant the accuracy of information provided in package inserts or herein. Medical decisions are the sole responsibility of health care providers and their patients, who are encouraged to carefully evaluate all potential risks and benefits associated with the use of any medical product or procedure including ultrasound contrast agents and (CEUS).


 

Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?

Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?

February 8, 2020 — Clinical Imaging
Authors: Zehao Tan, Wey Chyi Teoh, Kang Min Wong, Gervais Khin-Lin Wansaicheong, Kumaresan Sandrasegaran
2020DOI:https://doi.org/10.1016/j.clinimag.2020.02.002
Abstract
Purpose
To study the comparative performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced CT or MRI (CECT/MR) in evaluating liver lesions using the LI-RADS guidelines.
Methods
Retrospective analysis of radiology database from July 2010 to April 2017 revealed 228 patients who had CECT/MR and CEUS. Patients at risk of hepatocellular carcinoma (HCC), had contemporaneous CEUS and CECT/CEMR studies within 3 months and adequate follow up were (read more…)

The 34th Annual Advances in Contrast Ultrasound International Bubble Conference 2019

The 34th Annual Advances in Contrast Ultrasound International Bubble Conference 2019

Echo Research and Practice
Authors:  Stella Kyung, Alan Brett Goldberg, Steven Feinstein, Stephanie Wilson, Sharon L. Mulvagh and Petros Nihoyannopulos
Read full article at: https://erp.bioscientifica.com/view/journals/echo/aop/erp-19-0055/erp-19-0055.xml
Abstract
The 34th annual Advances in Contrast Ultrasound (ACU) International Bubble Conference convened in Chicago, IL on September 5-6, 2019 to feature new directions of research, pre-clinical and first-in-man clinical trials and novel clinical applications highlighting the diversity and utility of contrast enhanced ultrasound (CEUS). An expert group comprised of clinicians, engineers, basic scientists, government officials, attorneys, and (read more…)

Lantheus touts new study on contrast echocardiography

Lantheus touts new study on contrast echocardiography

February 4, 2020 — AuntMinnie.com
By AuntMinnie.com staff writers
Lantheus Medical Imaging parent company Lantheus Holdings announced the results of its Benefit 1 clinical trial, which evaluated the potential advantages of using its Definity ultrasound contrast agent to evaluate heart failure.
The trial results indicated that contrast-enhanced echocardiography led to statistically significant improvements in measurements of left ventricular diastolic and systolic blood flow as well as stroke volume for the 145 trial participants, compared with unenhanced echocardiography and cardiac MRI.
However, contrast-enhanced (read more…)

New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer

New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer

January 21, 2020 — Dovepress
Authors: Yuhang Tian,* Zhao Liu,* Haoyan Tan, Jiahui Hou, Xin Wen, Fan Yang, Wen Cheng
Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin 150080, People’s Republic of China
DOI https://doi.org/10.2147/IJN.S201208
Abstract:
Ultrasound-mediated targeted delivery (UMTD), a novel delivery modality of therapeutic materials based on ultrasound, shows great potential in biomedical applications. By coupling ultrasound contrast agents with therapeutic materials, UMTD combines the advantages of ultrasound imaging and carrier, which benefit deep tissue penetration and high concentration aggregation. In (read more…)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes:

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes:

The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)
European Heart Journal — January 14, 2020
Authors: Juhani Knuuti, William Wijns, Antti Saraste, Davide Capodanno, Emanuele Barbato, Christian Funck-Brentano, Eva Prescott, Robert F Storey, Christi Deaton, Thomas Cuisset et al
European Heart Journal, Volume 41, Issue 3, 14 January 2020, Pages 407–477, https://doi.org/10.1093/eurheartj/ehz425
New/revised concepts in 2019
The Guidelines have been revised to focus on CCS instead of stable CAD.
This change emphasizes the fact (read more…)

Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound

Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound

January 8, 2020 — European Radiology
Authors: Dan Liu, Fei Liu, Xiaoyan Xie, Liya Su, Ming Liu, Xiaohua Xie, Ming Kuang Guangliang Huang, Yuqi Wang, Hui Zhou, Kun Wang, Manxia Lin, Jie Tian
https://doi.org/10.1007/s00330-019-06553-6
Abstract
Objectives
We aimed to establish and validate an artificial intelligence–based radiomics strategy for predicting personalized responses of hepatocellular carcinoma (HCC) to first transarterial chemoembolization (TACE) session by quantitatively analyzing contrast-enhanced ultrasound (CEUS) cines.
Methods
One hundred and thirty HCC patients (89 for training, 41 for validation), who received ultrasound examination (CEUS (read more…)

Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection

Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection

January 8, 2020 — Uro Today
Authors: I Gupta, B Freid, V Masarapu, P Machado, E Trabulsi, K Wallace, E Halpern, F Forsberg
Thomas Jefferson University, Philadelphia, PA 19107, USA., GE Global Research, Niskayuna NY 12309, USA., Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address: flemming.forsberg@jefferson.edu.
http://www.ncbi.nlm.nih.gov/pubmed/31899231
To assess the PCa detection rates of contrast-enhanced, transrectal subharmonic ultrasound imaging (SHI).
This IRB-approved study enrolled 55 subjects. The initial 5 subjects were studied for SHI optimization, while the remaining 50 were evaluated with (read more…)

World’s first cancer treatment being trialed in NHS hospitals could make chemotherapy ‘more effective by using BUBBLES to help kill tumors’

World’s first cancer treatment being trialed in NHS hospitals could make chemotherapy ‘more effective by using BUBBLES to help kill tumors’

Acoustic cluster therapy involves injecting microbubbles and liquid droplets
Ultrasound used to make bubbles grow larger and stretch the tumor’s walls
Increases chance of chemo drugs reaching cancer cells and not healthy ones

Daily Mail (Online) — December 18, 2019
By Connor Boyd, Health Reporter
NHS hospitals are trialling a world-first way of delivering chemotherapy to try and make the grueling cancer treatment more effective. It involves using tiny bubbles to get more drugs inside tumors without damaging healthy cells, a brutal side effect of (read more…)

Contrast-enhanced ultrasound in detecting wall invasion and differentiating bland from tumor thrombus during robot-assisted inferior vena cava thrombectomy for renal cell carcinoma

Contrast-enhanced ultrasound in detecting wall invasion and differentiating bland from tumor thrombus during robot-assisted inferior vena cava thrombectomy for renal cell carcinoma

Uro Today — December 6, 2019
Vena cava thrombus is one of the main clinical manifestations of locally aggressive renal cell carcinoma (RCC). Inferior vena cava (IVC) wall invasion and presence of bland thrombus could affect the surgical outcome. This study aims to assess the value of contrast-enhanced ultrasound (CEUS) in detecting wall invasion and differentiating bland thrombus from tumor thrombus during robot-assisted IVC thrombectomy for RCC.
The intraoperative CEUS findings of 60 patients with RCC accompanied by IVC tumor thrombus were (read more…)

Ultrasound Can Open Blood-Brain Barrier; Treatment could improve drug penetration and toxin removal in Alzheimer’s patients

Ultrasound Can Open Blood-Brain Barrier; Treatment could improve drug penetration and toxin removal in Alzheimer’s patients

December 05, 2019 — MedPage Today
By Ed Susman
In preliminary studies, focused ultrasound directed at the blood-brain barrier briefly made it more porous, which could be a means to allow drugs into Alzheimer’s patients’ brains or permit toxins to escape.
In the phase II safety trial, researchers treated three women diagnosed with Alzheimer’s disease with low-intensity focused ultrasound who had been administered a micro-bubble contrast agent to assess the safety of using the device and treatment.
“The results are promising,” said Rashi Mehta, (read more…)